Founder: Commercial insurance increased pending AI+ leading a new round of medical revolution.

Founder's research report stated that this year's reform in the pharmaceutical industry is an optimization of the existing payment structure, with the expectation to obtain longer-term payment capabilities. The catalytic effect in the pharmaceutical industry is emerging, and a positive outlook is held for future growth. Currently, the core conflicts in the payment sector are gradually being resolved, with the vigorous development of commercial insurance opening up the second growth curve in the medical and health market. This year, the AI revolution is sweeping across the globe and is poised to lead a new wave of medical revolution. It is advised to adopt a "dumbbell-shaped" configuration in the pharmaceutical industry, focusing on innovation + outbound growth direction + stable direction of dividend stocks. In the growth direction, options include innovative drugs, data elements, high-value consumables, etc., while in the stable direction, options include traditional Chinese medicine, pharmacies, and certain medical service areas. Key points from the Founder's report are as follows: The catalytic effect in the pharmaceutical industry is emerging, with a positive outlook for future growth. This year, the pharmaceutical industry has successively experienced a series of events such as medical anti-corruption, off-site price comparison, medical insurance verification, Drgs cost control, etc., resulting in the index significantly underperforming other industries. Investors generally have concerns about the long-term space and payment capabilities in the pharmaceutical industry. All the events experienced this year are optimization of the existing payment structure, aiming to obtain longer-term payment capabilities. In fact, after October, the industry has already undergone a major turning point, with the country starting to consider vigorously developing commercial insurance business, positive incremental changes in the payment sector, and the increasing maturity of AI applications in the industry, which will lead the next wave of medical revolution. Core conflicts in the payment sector are gradually being resolved, and commercial insurance is opening up the second growth curve. The national medical insurance work conference has already concluded, highlighting the support for and promotion of commercial insurance institutions to accelerate the establishment of long-term care insurance products, promote commercial insurance, charity mutual aid, and synchronize settlement with basic medical insurance. The support for inclusive commercial insurance to include innovative drugs for reimbursement, researching and exploring the formation of a third-class catalog. It is evident that the opening up of the payment sector has been included in the focus of work in the coming years, with the aim of improving the penetration rate of commercial insurance, expanding scale, and reducing underwriting costs through medical insurance data openness, simultaneous settlement within hospitals, gradually addressing the current issue of insufficient payment capabilities in medical insurance funds, and opening up the second growth curve in the medical and health market through the vigorous development of commercial insurance. AI+ trend is sweeping the globe, leading a new wave of medical revolution. The AI revolution is sweeping across the globe, with AI in the medical field leveraging neural networks and computer vision technology to rapidly analyze imaging data such as CT and MRI, accurately identify lesions, generate structured reports, help doctors quickly make diagnoses, significantly improve the efficiency of imaging data processing and the accuracy of early disease screening. At the same time, AI can combine anatomical structures and diagnostic logic to provide reliable auxiliary support for doctors, further enhancing the accuracy and consistency of imaging diagnoses. Leading companies are actively deploying AI in medical imaging equipment, building intelligent product systems through independent research and development and strategic cooperation, such as Shenzhen Mindray Bio-Medical Electronics, Shanghai United Imaging Healthcare, Neusoft Corporation, Beijing Wandong Medical Technology, etc. Investment strategy: Regarding the current investment strategy, it is recommended to adopt a "dumbbell-shaped" configuration in the pharmaceutical industry, focusing on the growth direction of innovation + outbound + stable dividend stocks. In the growth direction, options include innovative drugs, data elements, high-value consumables, etc., with recommended companies such as Jiangsu Hengrui Pharmaceuticals, Sichuan Kelun Pharmaceutical, AKESO, InventisBio, China Reform Health Management and Services Group, Sichuan Jiuyuan Yinhai Software, APT Medical Inc., Shanghai Microport Ep Medtech, Shenzhen Mindray Bio-Medical Electronics, Shanghai United Imaging Healthcare, Shanghai Runda Medical Technology, etc. In the stable direction, options include traditional Chinese medicine, pharmacies, and certain medical service areas, with recommended companies such as China Resources Sanjiu Medical & Pharmaceutical, Henan Lingrui Pharmaceutical, Mayinglong Pharmaceutical Group, Hubei Jumpcan Pharmaceutical, DaShenLin Pharmaceutical Group, JZJ Chain Drugstore Corporation, Yixintang Pharmaceutical, Topchoice Medical, Xi'An International Medical Investment, etc. Risk warning: Risks of commercial insurance expansion falling short of expectations, risks of AI development falling short of expectations, risks of medical insurance payment pressure exceeding expectations, etc.He is systemic risk.Hola, cmo ests hoy?